Cormorant Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Cormorant Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,500,000	Closed	-$41.4M	–	62
2023 Q2	$41.4M	Sell	1,500,000 -200,000	-12%	-$5.01M	2.32%	9
2023 Q1	$39.1M	Buy	+1,700,000	New	+$28.6M	2.58%	11
2018 Q3	–	Sell	-382,139	Closed	-$2.57M	–	67
2018 Q2	$2.57M	Hold	382,139	–	–	0.19%	56
2018 Q1	$3.28M	Sell	382,139 -17,861	-4%	-$336K	0.24%	45
2017 Q4	$8.32M	Sell	400,000 -100,000	-20%	-$1.77M	0.87%	29
2017 Q3	$8.84M	Hold	500,000	–	–	1.56%	24
2017 Q2	$5.66M	Sell	500,000 -183,600	-27%	-$1.96M	0.94%	28
2017 Q1	$8.76M	Sell	683,600 -36,400	-5%	-$587K	1.27%	29
2016 Q4	$15.8M	Sell	720,000 -80,000	-10%	-$1.78M	2.13%	15
2016 Q3	$16.9M	Buy	+800,000	New	+$10.9M	1.86%	18

Other funds holding PTGX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cormorant Asset Management's PTGX Position: Q3 2023 in Review

Cormorant Asset Management sold out of Protagonist Therapeutics (PTGX) in Q3 2023, closing a stake of 1,500,000 shares — an estimated $41.4M sold.

Cormorant Asset Management first reported a position in PTGX in Q3 2016 and held it in 10 quarters. The position peaked at $41.4M in Q2 2023. 144 funds tracked by Wall St. Rank hold PTGX as of Q3 2023.

Cormorant Asset Management reported no remaining Protagonist Therapeutics position as of Q3 2023 after selling out during the quarter.
Cormorant Asset Management sold 1,500,000 Protagonist Therapeutics shares in Q3 2023, an estimated $41.4M.
Cormorant Asset Management first reported a position in Protagonist Therapeutics in Q3 2016 and held it in 10 quarters.
Cormorant Asset Management's Protagonist Therapeutics position peaked at $41.4M in Q2 2023.
144 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2023.

Based on Cormorant Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.